Evaluation of DNA adduction of AZT in peripheral blood leukocytes of HIV-infected individuals by 32P-post-labeling thin-layer chromatography: A feasibility study

Jerry M. Huang, Kathryn Anastos, Esther Robison, Ruijin Shi, Kathy Freeman, Howard Strickler, J. J. Steinberg

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


3′-Azido-3′-deoxythymidine (AZT, Zidovudine) has been effectively used for HIV infection treatment. It inhibits virus reproduction through viral reverse transcriptase inhibition. However, the side effects of this anti-retroviral drug might be cumulative, particularly in its effects on the patients' DNA. As a nucleoside analogue, AZT might incorporate into hosts' DNA, and then form DNA adducts. This may result in potential long-term risks of mutagenesis in AIDS patients who received therapy. In this feasibility study, a 32P-post-labeling thin-layer chromatography (TLC) assay is successfully used to measure AZT-DNA analogue and adducts formed in peripheral blood leukocytes of AZT treated patients. There are DNA analogue/adducts measured in all four AZT treated patients' DNA specimens. This assay is reliable with the significant coefficient of correlation in both intra-assay (r = 0.8761, P = 0.0001) and inter-assay (r = 0.8761, P = 0.0001).

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalJournal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Issue number1
StatePublished - Oct 15 2004


  • 3′-Azido-3′-deoxythymidine
  • DNA

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Clinical Biochemistry
  • Cell Biology


Dive into the research topics of 'Evaluation of DNA adduction of AZT in peripheral blood leukocytes of HIV-infected individuals by <sup>32</sup>P-post-labeling thin-layer chromatography: A feasibility study'. Together they form a unique fingerprint.

Cite this